This inventor holds 34 USPTO granted patents, primarily in Pharmaceutical Chemistry. Top assignees: Schering Aktiengesellschaft, A/s Ferrosan, Hoffmann-La Roche Inc.. Active years: 1976-1991.
Company Filing History:
33 out of 1,409 
2 out of 41 
1 out of 5,020 
Years Active: 1976-1991
Areas of Expertise:
Title: The Innovative Mind of Ulrich Eder
Introduction
Ulrich Eder, based in Berlin, Germany, is a prolific inventor known for his significant contributions to the field of chemical compounds. With a remarkable portfolio of 34 patents, Eder has focused much of his research on developing novel derivatives and compounds that hold therapeutic potential.
Latest Patents
Among his latest patents, Eder has introduced innovative compounds such as beta-carbolin-3-carboxylic acid derivatives, which prove useful in treating various medical conditions. One of these derivatives is characterized by the formula where X can be oxygen, sulfur, or a nitrogen group with varying alkyl and cycloalkyl side chains. Additionally, he has worked on novel ergolinyl compounds that are nitrogen-substituted in the 8-position, which also encompass physiologically compatible salts, showcasing his dedication to exploring diverse chemical structures for potential therapeutic applications.
Career Highlights
Eder’s career includes significant tenure at renowned companies such as Schering Aktiengesellschaft and A/S Ferrosan. His work at these institutions has advanced the research and application of chemical compounds in medicinal chemistry, making substantial contributions to the pharmaceutical industry.
Collaborations
Throughout his career, Eder has collaborated with notable colleagues, including Rudolf Wiechert and Gerhard Sauer. These collaborations have undoubtedly enriched his research endeavors and contributed to the successful development and patenting of innovative compounds.
Conclusion
Ulrich Eder’s contributions as an inventor underline the impact of innovation on medicine and chemistry. His extensive patent portfolio reflects a deep commitment to research and development, leading to significant advancements in therapeutic compounds. As he continues to innovate, his work remains influential in the pursuit of effective treatments and improved health outcomes.